Joint Sales Promotion Agreement for Allegion® Eyelid Cream Signed ｜ July 2026

Overview of the Contract Signing

Kyorin Pharmaceutical has entered into a joint sales promotion agreement with Santen Pharmaceutical to strengthen the sales of Allegion® Eyelid Cream. Santen will handle manufacturing, sales, and promotion within the ophthalmology field, while Kyorin will expand to non-ophthalmic medical institutions. The drug, launched in May 2024, aims to promote widespread adoption, contributing to improved QOL for patients.

Future Outlook and Impact

This contract will provide a new treatment option for allergic conjunctivitis and facilitate business expansion while enhancing patients' quality of life. Specific impacts on the consolidated performance for the fiscal year ending March 2027 have not been disclosed, but increased sales activities are expected to support long-term growth.